Centre for Intellectual Disability and Mental Health, GGZ Drenthe, Assen, The Netherlands.
Department of Child and Adolescent Psychiatry, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
J Intellect Disabil Res. 2019 May;63(5):418-428. doi: 10.1111/jir.12584. Epub 2019 Jan 4.
Many people with intellectual disabilities use risperidone long term for the management of challenging behaviours, despite its limited proof of effectiveness and its clear association with adverse events. Therefore, this study aimed to investigate the effectiveness of ongoing treatment with risperidone in reducing challenging behaviours versus controlled discontinuation on behaviour and health parameters.
This was a placebo-controlled, double-blind, randomised discontinuation trial of risperidone. In the discontinuation group, risperidone was gradually replaced by a placebo over 14 weeks, while the control group maintained their existing dosage. Eight weeks after discontinuation, behaviour (as measured by the 'Aberrant Behavior Checklist') and health parameters (dyskinesia, akathisia, parkinsonism, weight, waist circumference, sedation and laboratory outcomes) were compared in both groups.
A total of 25 participants were included in the trial, of which 11 were randomised into the discontinuation group and 14 were randomised into the continued treatment group. In the discontinuation group, 82% completely withdrew from risperidone. There was no significant change in irritability, compared with the continuation group, although there was a GroupTime effects on stereotypical behaviour in favour of the continuation group. Significant GroupTime effects were also found for weight, waist, body mass index, prolactin levels and testosterone levels, with beneficial effects for the discontinuation group.
Discontinuation of long-term risperidone for reducing challenging behaviours is possible, without an increase in irritability. Discontinuation of risperidone may have beneficial effects on weight, waist circumference, prolactin levels and testosterone levels. The study suffered from difficulties in achieving the required sample size, which affected study power and generalizability.
许多智障人士长期使用利培酮来控制挑战性行为,尽管其疗效有限,且明确与不良事件相关。因此,本研究旨在调查持续使用利培酮治疗与对照停药对行为和健康参数的影响。
这是一项利培酮的安慰剂对照、双盲、随机停药试验。在停药组中,利培酮在 14 周内逐渐被安慰剂替代,而对照组则维持其现有剂量。停药 8 周后,比较两组的行为(以“异常行为检查表”衡量)和健康参数(运动障碍、静坐不能、帕金森病、体重、腰围、镇静和实验室结果)。
共有 25 名参与者参加了试验,其中 11 名被随机分配到停药组,14 名被随机分配到继续治疗组。在停药组中,82%的患者完全停止使用利培酮。与继续治疗组相比,烦躁情绪没有明显变化,尽管在刻板行为方面存在组间时间效应,对继续治疗组有利。体重、腰围、体重指数、催乳素水平和睾酮水平也存在显著的组间时间效应,停药组有益。
长期停用利培酮以减少挑战性行为是可能的,不会增加烦躁感。停用利培酮可能对体重、腰围、催乳素水平和睾酮水平有益。该研究因难以达到所需的样本量而面临困难,这影响了研究的效力和推广性。